NCT02733250View on ClinicalTrials.gov

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

April 13, 2019

Study Completion Date

December 13, 2019

Conditions
Lung Cancer
Interventions
BIOLOGICAL

Pembrolizumab

200mg IV Day 1 of each 21 cycles

DRUG

Nab-Paclitaxel

100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles

Trial Locations (2)

H2X 3E4

Centre hospitalier de l'université de Montréal (CHUM), Montreal

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

OTHER

collaborator

Merck Canada Inc.

INDUSTRY

collaborator

Celgene

INDUSTRY

collaborator

Jewish General Hospital

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER